See more : Sumco Corporation (SUOPY) Income Statement Analysis – Financial Results
Complete financial analysis of Igene Biotechnology, Inc. (IGNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Igene Biotechnology, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- Pan American Energy Corp. (PAANF) Income Statement Analysis – Financial Results
- Home First Finance Company India Limited (HOMEFIRST.BO) Income Statement Analysis – Financial Results
- AMTE Power plc (AMTE.L) Income Statement Analysis – Financial Results
- Avenira Limited (AEV.AX) Income Statement Analysis – Financial Results
- Pivotree Inc. (PVT.V) Income Statement Analysis – Financial Results
Igene Biotechnology, Inc. (IGNE)
About Igene Biotechnology, Inc.
Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. The company supplies natural astaxanthin, a nutrient used as a source of pigment for coloring farmed salmon and trout species. It also supplies ingredients and finished products to the nutraceutical and feed industry. The company also provides research and development services for microbial strain improvement and fermentation process development and scale up from shake flask, to pilot plant, to commercial sized fermentors; and analytical chemistry services for identification and quantization of carotenoids in foods, feeds, and animal tissues, including verification of wild versus farm raised salmonids. The company was formerly known as IGI Biotechnology, Inc. and changed its name to IGENE Biotechnology, Inc. in April 1986. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland.
| Metric | 2009 | 2008 | 2007 | 2006 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.96M | 7.64M | 2.29M | 0.00 | 463.49K | 3.49M | 4.18M | 702.53K | 18.13K |
| Cost of Revenue | 2.94M | 6.40M | 1.68M | 0.00 | 446.14K | 3.17M | 3.52M | 691.16K | 83.92K |
| Gross Profit | 1.02M | 1.25M | 605.10K | 0.00 | 17.34K | 324.13K | 663.61K | 11.38K | -65.79K |
| Gross Profit Ratio | 25.66% | 16.34% | 26.46% | 0.00% | 3.74% | 9.28% | 15.87% | 1.62% | -362.84% |
| Research & Development | 1.85M | 1.66M | 983.61K | 847.60K | 745.36K | 609.78K | 536.64K | 355.66K | 350.66K |
| General & Administrative | 838.06K | 1.05M | 972.97K | 1.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 387.92K | 731.09K | 158.10K | 98.24K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.23M | 1.78M | 1.13M | 1.12M | 1.02M | 1.52M | 1.70M | 1.06M | 1.35M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 990.93K | 3.44M | 537.98K | 307.37K | 642.08K | 2.18M | 2.30M | 1.52M | 1.77M |
| Cost & Expenses | 3.93M | 9.83M | 2.22M | 307.37K | 1.09M | 5.34M | 5.82M | 2.21M | 1.86M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.37K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 97.52K | 2.03M | 2.16M | 753.79K | 897.54K | 903.36K | 813.42K | 709.83K | 0.00 |
| Depreciation & Amortization | 150.72K | 107.82K | 12.44K | 16.49K | 83.79K | 177.43K | 133.49K | 102.22K | 74.05K |
| EBITDA | -851.29K | -2.08M | 324.58K | -307.52K | -540.96K | -1.67M | -1.50M | -1.41M | -1.23M |
| EBITDA Ratio | -21.51% | -30.17% | 2.45% | 0.00% | -358.17% | -46.58% | -5.21% | -195.23% | -9,786.62% |
| Operating Income | -1.07M | -2.19M | 237.94K | -416.52K | -624.74K | -1.85M | -1.64M | -1.51M | -1.84M |
| Operating Income Ratio | -27.03% | -28.63% | 10.41% | 0.00% | -134.79% | -53.01% | -39.18% | -214.89% | -10,143.68% |
| Total Other Income/Expenses | 1.07M | 225.81K | 23.62K | 14.54K | 204.61K | -901.99K | -2.03M | -35.85K | -521.57K |
| Income Before Tax | -43.23K | -1.96M | 261.57K | -401.98K | -420.13K | -2.75M | -3.67M | -1.55M | -1.83M |
| Income Before Tax Ratio | -1.09% | -25.67% | 11.44% | 0.00% | -90.65% | -78.84% | -87.85% | -219.99% | -10,092.33% |
| Income Tax Expense | 165.38K | 1.80M | 1.97M | 848.40K | 659.91K | 1.34M | 2.03M | 745.67K | 686.19K |
| Net Income | -140.75K | -3.99M | -1.90M | -1.16M | -2.20M | -3.19M | -3.67M | -2.26M | -2.53M |
| Net Income Ratio | -3.56% | -52.21% | -83.05% | 0.00% | -474.48% | -91.36% | -87.85% | -321.03% | -13,928.30% |
| EPS | 0.00 | -0.02 | -0.02 | -0.01 | -0.02 | -0.04 | -0.05 | -0.04 | -0.07 |
| EPS Diluted | 0.00 | -0.02 | -0.02 | -0.01 | -0.02 | -0.04 | -0.05 | -0.04 | -0.07 |
| Weighted Avg Shares Out | 1.54B | 187.04M | 109.68M | 108.39M | 90.44M | 81.54M | 75.85M | 56.04M | 33.98M |
| Weighted Avg Shares Out (Dil) | 1.54B | 187.04M | 109.68M | 108.39M | 90.44M | 81.54M | 75.85M | 56.04M | 33.98M |
Source: https://incomestatements.info
Category: Stock Reports